Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference
February 22 2017 - 5:30AM
Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief
Executive Officer, Dr. Mark Heffernan, is scheduled to present at
the Cowen and Company 37th Annual Health Care Conference in
Boston, Massachusetts on Monday, March 6th at 1:20PM ET.
Dr. Heffernan will discuss Nexvet’s pivotal-stage
clinical programs for chronic pain in cats and dogs, consisting of
ranevetmab and frunevetmab; the significant progress made at the
Company’s manufacturing facility, BioNua, as well as the Company’s
pipeline.
The presentation will be available on the investor
section of Nexvet's website at
http://ir.nexvet.com following the completion of
the event.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologic therapeutics
company focused on transforming the therapeutic market for
companion animals, such as dogs and cats, by developing and
commercializing novel, species-specific biologics. Nexvet’s
proprietary PETization™ platform is designed to rapidly design
monoclonal antibodies (mAbs) that are recognized as “self” or
“native” by an animal’s immune system, a property Nexvet refers to
as “100% species-specificity.” Nexvet’s product candidates build
upon the safety and efficacy data from clinically tested human
therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and
incentives to build a vertically integrated biopharmaceutical
company, which conducts drug discovery in Australia, conducts
clinical development in the United States and Europe and
conducts manufacturing in Ireland.
Further information:
Investors
Candice Knoll
Blueprint Life Science Group
+1 415-375-3340 Ext. 4
cknoll@bplifescience.com
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Mar 2024 to Apr 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Apr 2023 to Apr 2024